<code id='E266DA2C1D'></code><style id='E266DA2C1D'></style>
    • <acronym id='E266DA2C1D'></acronym>
      <center id='E266DA2C1D'><center id='E266DA2C1D'><tfoot id='E266DA2C1D'></tfoot></center><abbr id='E266DA2C1D'><dir id='E266DA2C1D'><tfoot id='E266DA2C1D'></tfoot><noframes id='E266DA2C1D'>

    • <optgroup id='E266DA2C1D'><strike id='E266DA2C1D'><sup id='E266DA2C1D'></sup></strike><code id='E266DA2C1D'></code></optgroup>
        1. <b id='E266DA2C1D'><label id='E266DA2C1D'><select id='E266DA2C1D'><dt id='E266DA2C1D'><span id='E266DA2C1D'></span></dt></select></label></b><u id='E266DA2C1D'></u>
          <i id='E266DA2C1D'><strike id='E266DA2C1D'><tt id='E266DA2C1D'><pre id='E266DA2C1D'></pre></tt></strike></i>

          Home / comprehensive / focus

          focus


          focus

          author:hotspot    Page View:18

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In